• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Alphatec Holdings Inc.

    5/8/25 4:21:16 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care
    Get the next $ATEC alert in real time by email
    DEFA14A 1 atec_2025_proxy_supp.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No.)

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material Pursuant to §240.14a-12

     

    ALPHATEC HOLDINGS, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

     

    img262709475_0.jpg

     

     

    SUPPLEMENT DATED MAY 8, 2025
    TO THE PROXY STATEMENT FOR THE
    ANNUAL MEETING OF ALPHATEC HOLDINGS, INC.
    TO BE HELD JUNE 11, 2025

    Explanatory Note

    This supplement to the Proxy Statement dated April 25, 2025 (the “Proxy Statement”) of Alphatec Holdings, Inc. (the “Company”) amends and restates the disclosure contained in the Proxy Statement regarding voting on Proposal 4. The Proxy Statement inadvertently indicates that banks, brokers and other nominees do not have authority to vote shares held in street name on Proposal 4 without receiving voting instruction from the beneficial owner of such shares. However, under applicable regulations, a proposal to amend to the Company’s Certificate of Incorporation solely to increase the number of authorized shares is considered routine and banks, brokers and other nominees do have authority to vote shares held in street name if the beneficial holder of such shares does not provide voting instructions. As a result, the following sections of the Proxy Statement are amended and restated as follows:

    Will My Shares be Voted if I Do Not Vote?

    If your shares are registered in your name or if you have stock certificates, they will not be counted if you do not vote as described above under "How Do I Vote?"

    If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above under "How Do I Vote?," the bank, broker or other nominee that holds your shares has the authority to vote your uninstructed shares on Proposals 2 and 4, as these are considered routine matters on which the bank, broker or other nominee has discretionary authority to vote. Therefore, we encourage you to provide voting instructions to your bank, broker or other nominee. This ensures your shares will be voted at the Annual Meeting and in the manner you desire. A "broker non-vote" will occur if your broker cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker chooses not to vote on a matter for which it does have discretionary voting authority.

    Your bank, broker or other nominee does not have the ability to vote your uninstructed shares in respect of Proposals 1, 3 or 5. Thus, if you hold your shares in street name, it is critical that you cast your vote if you want your vote to be counted for the foregoing proposals. If you do not instruct your bank, broker or other nominee how to vote with respect to the foregoing proposals, no votes will be cast on these proposals on your behalf.

     


     

    What Vote is Required to Approve Each Proposal and How are Votes Counted?

     

    Proposal 1: Election of Directors

    The nominees for director who receive the most votes (also known as a "plurality" of the votes cast) will be elected. You may vote either FOR all of the nominees, WITHHOLD your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote customers’ uninstructed shares held by the firms in street name for the election of directors. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.

    Proposal 2: Ratify Selection of Independent Registered Public Accounting Firm

    The affirmative vote of a majority of the votes cast affirmatively or negatively for this proposal is required to ratify the selection of our independent registered public accounting firm. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote customers’ uninstructed shares held by the firms in street name on this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote. We are not required to obtain the approval of our stockholders to select our independent registered public accounting firm. However, if our stockholders do not ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ended December 31, 2025, the Audit Committee of our Board of Directors will reconsider whether or not to retain Deloitte & Touche LLP.

     

     

    Proposal 3: Approval of Amendment to our 2016 Equity Incentive Plan

    The affirmative vote of a majority of the shares cast affirmatively or negatively for this proposal is required to amend our 2016 Equity Incentive Plan. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote customers’ uninstructed shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote.

     

     

     


     

    Proposal 4: Approval of an Amendment to our Certificate of Incorporation

    The affirmative vote of a majority of the shares cast affirmatively or negatively for this proposal is required to amend our Certificate of Incorporation to increase the number of authorized shares of our stock from 220,000,000 to 420,000,000 and to increase the number of authorized shares of our common stock from 200,000,000 to 400,000,000. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote customers’ uninstructed shares held by the firms in street name on this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote.

     

     

    Proposal 5: Approval, on an Advisory Basis, of the Compensation of our Named Executive Officers

    The affirmative vote of a majority of the votes cast affirmatively or negatively for this proposal is required to approve, on an advisory basis, the compensation of our named executive officers. Abstentions have no effect on the results of this vote. Brokerage firms do not have authority to vote customers’ uninstructed shares held by the firms in street name on this proposal. As a result, any shares not voted by a customer will be treated as a broker non-vote. Such broker non-votes will have no effect on the results of this vote. Although the advisory vote is non-binding, the Compensation Committee and the Board of Directors will review the voting results and take them into consideration when making future decisions regarding executive compensation.

     

    Required Vote

    Proxies already received will continue to be voted as instructed unless otherwise revoked or changed by a subsequent proxy. If you have already voted your shares and you do not wish to change your vote, you do not need to re-cast your vote.

     

     


    Get the next $ATEC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATEC

    DatePrice TargetRatingAnalyst
    6/16/2025$18.00Buy
    Lake Street
    8/1/2024Overweight → Equal-Weight
    Morgan Stanley
    7/8/2024$19.00Overweight
    Barclays
    2/9/2024$26.00Overweight
    Wells Fargo
    12/19/2023$16.00 → $18.00Buy
    Needham
    10/20/2023$22.00Buy
    ROTH MKM
    10/12/2022$12.00Buy
    Jefferies
    9/12/2022$13.00Overweight
    Morgan Stanley
    More analyst ratings

    $ATEC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on Alphatec with a new price target

    Lake Street resumed coverage of Alphatec with a rating of Buy and set a new price target of $18.00

    6/16/25 8:53:19 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Alphatec downgraded by Morgan Stanley

    Morgan Stanley downgraded Alphatec from Overweight to Equal-Weight

    8/1/24 3:06:35 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Alphatec with a new price target

    Barclays initiated coverage of Alphatec with a rating of Overweight and set a new price target of $19.00

    7/8/24 7:34:11 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bakst Evan bought $201,600 worth of shares (35,000 units at $5.76) (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/26/24 4:32:07 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Pelizzon David R bought $149,998 worth of shares (25,796 units at $5.81), increasing direct ownership by 8% to 331,696 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/26/24 4:27:25 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Director Demski David M bought $283,500 worth of shares (50,000 units at $5.67), increasing direct ownership by 21% to 288,441 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/21/24 10:00:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATEC to Participate in Upcoming Conferences

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conferences: The 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025. The RBCCM Medical Supplies & Devices Virtual Symposium virtually on August 18, 2025, from 10:00am – 11:00am ET. The Piper Sandler MedTech and Diagnostics West Coast Bus Tour at The Ritz Carlton Laguna Niguel in Dana Point, CA at 7:55am PT. The Wells Fargo 2025 Healthcare Conference beginning on September 3, 2025, at The Encore Boston Harbor in Everett, MA, with a fireside c

    8/8/25 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC Reports Second Quarter 2025 Financial Results and Raises Full-Year Guidance

    Surgical revenue grew 29% to $168 million Total revenue grew $40 million or 27.5% Full-year revenue and profitability guidance increased Alphatec Holdings, Inc. (NASDAQ:ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2025, and recent corporate highlights. Second Quarter 2025 Financial Results   Quarter Ended June 30, 2025 Total revenue $186 million GAAP gross margin 70% Non-GAAP gross margin 70% GAAP operating expenses $142 million Non-GAAP operating expenses $122 milli

    7/31/25 4:05:00 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report Second Quarter 2025 Financial Results on July 31, 2025

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.

    7/17/25 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    SEC Filings

    View All

    SEC Form 144 filed by Alphatec Holdings Inc.

    144 - Alphatec Holdings, Inc. (0001350653) (Subject)

    8/4/25 4:22:30 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Alphatec Holdings Inc.

    10-Q - Alphatec Holdings, Inc. (0001350653) (Filer)

    7/31/25 4:51:35 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    Alphatec Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alphatec Holdings, Inc. (0001350653) (Filer)

    7/31/25 4:19:03 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF OPERATING OFFICER Lish Scott sold $101,231 worth of shares (6,323 units at $16.01), decreasing direct ownership by 0.95% to 658,707 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/21/25 7:09:35 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    CHIEF OPERATING OFFICER Lish Scott sold $148,832 worth of shares (9,302 units at $16.00), decreasing direct ownership by 1% to 665,030 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/15/25 5:42:21 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    CEO Miles Patrick gifted 10,000 shares, decreasing direct ownership by 0.17% to 5,864,078 units (SEC Form 4)

    4 - Alphatec Holdings, Inc. (0001350653) (Issuer)

    8/14/25 6:20:24 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Leadership Updates

    Live Leadership Updates

    View All

    Paragon 28 Appoints Dave Demski to Board of Directors

    Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

    12/11/24 9:00:00 AM ET
    $ATEC
    $FNA
    Medical/Dental Instruments
    Health Care

    Spineology® Appoints new Member to Leadership Team; Spine Veteran Emory Rooney joins as Executive Vice President of Sales

    Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri

    4/4/24 9:05:00 AM ET
    $ATEC
    $SYK
    Medical/Dental Instruments
    Health Care

    John Booth to Retire as CEO of Spineology Inc.

    Brian Snider Appointed New CEO Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director. Snider joins Spineology with nearly twenty years of progressive leadership experience in the

    11/9/23 9:00:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Financials

    Live finance-specific insights

    View All

    ATEC to Report Second Quarter 2025 Financial Results on July 31, 2025

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report second quarter 2025 financial results on July 31, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months.

    7/17/25 9:05:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report First Quarter 2025 Financial Results on May 1, 2025

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report first quarter 2025 financial results on May 1, 2025, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-In To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Inducemen

    4/14/25 9:00:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    ATEC to Report Third Quarter Financial Results on October 30, 2024

    Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that it will report third quarter 2024 financial results on October 30, 2024, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT / 4:30 p.m. ET. Webcast To access the live webcast, please visit the Investor Relations Section of ATEC's Corporate Website. Dial-in To dial into the live webcast, please register at this link. Access details will be shared via email. Replay A replay of the webcast will remain available through the Investor Relations Section of ATEC's Corporate Website for twelve months. Indu

    10/7/24 9:00:00 AM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    $ATEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Alphatec Holdings Inc.

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    11/12/24 8:04:57 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    3/22/24 7:57:56 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Alphatec Holdings Inc. (Amendment)

    SC 13D/A - Alphatec Holdings, Inc. (0001350653) (Subject)

    5/12/23 4:51:18 PM ET
    $ATEC
    Medical/Dental Instruments
    Health Care